|
|
New Developments in Transplant Rejection DrugsPublished by: Datamonitor Published: Oct. 21, 2002 - 37 Pages Table of ContentsOverview Introduction Companies need to consider their strategies for encouraging organ donation, but should avoid heavy-handed legislative efforts to escape negative publicity. In the field of transplant drugs R&D, six promising drugs are making their way to market. Two new drugs in the Novartis transplantology portfolio have been delayed; meanwhile, promising alternatives from Fujisawa and Isotechnika/ Roche are progressing through clinical trials. Scope Analysis of the issues and solutions surrounding the shortage of organ donors with epidemiological data by organ and year from the seven major markets Key data contrasting the number of organs transplanted in each of the major markets with the number of patients on waiting lists Analysis of six important drugs in development for transplant indications Report Highlights The greatest limiting factor in the transplant drugs market is the lack of donor organs. Pharmaceutical companies may consider political lobbying to encourage legislation imposing mandatory organ donation with optional “opt out”. Novartis’ Certican and Myfortic have been delayed. Regulatory filings have yet to be made for the US market, as Novartis waits on extra clinical trial data to strengthen its submissions. Datamonitor predicts that these drugs will not now be launched in the US until 2004. Of products in development, Fujisawa’s FK778 is of greatest potential. An agent that is both immunosuppressive and active against polyomaviruses has enormous potential. Reasons to Purchase Trial data: Target drug development to avoid costly mistakes Competitive analysis: Benchmark your company against the leaders Market analysis: Plan future product positioning with confidence DRIVERS AND TRENDS The greatest limiting factor in the transplant drugs market is the lack of donor organs. Pharmaceutical companies may consider political lobbying to encourage legislation imposing mandatory organ donation with optional “opt out”. Several countries, including Germany, have implemented systems of “presumed consent”, making everyone a potential organ donor at death Two Novartis drugs in development have been delayed, but other promising candidates from Fujisawa and Isotechnika/ Roche are progressing through trials EPIDEMIOLOGY AND RELATED ISSUES The organ transplant drug market is limited chiefly by the shortage of organs to transplant. Several countries have passed laws attempting to redress this situation. PIPELINE ANALYSIS Six key drugs are in development for transplant indications. The launches of Certican and Myfortic have been delayed; these products will now reach the key US market in 2004. DATASETS Table 1: Organ transplants and waiting lists, US, 1996-2000 Table 2: Organ transplants, Japan, 1995-2000 Table 3: Organ transplant waiting lists, Japan, 31/05/2002 Table 4: Organ transplants and waiting lists, Germany, 1998-2000 Table 5: Organ transplants and waiting lists, UK and Eire, 1996-2000 Table 6: Organ transplants and waiting lists, France, 1997-2001 Table 7: Organ transplants and waiting lists, Italy, 1997-2001 Table 8: Organ transplants and waiting lists, Spain, 1997-2001 Table 9: Late stage drugs in development for transplant indications AbstractIntroduction: Companies need to consider their strategies for encouraging organ donation, but should avoid heavy-handed legislative efforts to escape negative publicity. In the field of transplant drugs R&D, six promising drugs are making their way to market. Two new drugs in the Novartis transplantology portfolio have been delayed; meanwhile, promising alternatives from Fujisawa and Isotechnika/ Roche are progressing through clinical trials. Scope: * Analysis of the issues and solutions surrounding the shortage of organ donors with epidemiological data by organ and year from the seven major markets * Key data contrasting the number of organs transplanted in each of the major markets with the number of patients on waiting lists * Analysis of six important drugs in development for transplant indications. Report Highlights: The greatest limiting factor in the transplant drugs market is the lack of donor organs. Pharmaceutical companies may consider political lobbying to encourage legislation imposing mandatory organ donation with optional "opt out". Novartis' Certican and Myfortic have been delayed. Regulatory filings have yet to be made for the US market, as Novartis waits on extra clinical trial data to strengthen its submissions. Datamonitor predicts that these drugs will not now be launched in the US until 2004. Of products in development, Fujisawa's FK778 is of greatest potential. An agent that is both immunosuppressive and active against polyomaviruses has enormous potential. Reasons to Purchase: * Trial data: Target drug development to avoid costly mistakes * Competitive analysis: Benchmark your company against the leaders * Market analysis: Plan future product positioning with confidenceGet Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||